Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: J Heart Lung Transplant. 2018 Oct 1;38(4):408–417. doi: 10.1016/j.healun.2018.09.021

Fig. 3.

Fig. 3.

Intention to Treat Two Year Survival with Medical versus LVAD therapy. Kaplan-Meier survival was equivalent with medical therapy (MedaMACS cohort) compared to LVAD therapy (INTERMACS cohort). Medical therapy patients were censored at time of transplant, ventricular assist device placement, or last follow-up. LVAD therapy patients were censored at recovery, transplant, or last follow up. Shaded areas represent 70% confidence intervals.